MRNA Stock Recent News

Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, which posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine topped estimates, vaccine pipeline, growth outlook, and more.

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.

The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.

Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.

Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.

For a time, Cathie Wood was the hottest investor on Wall Street. Ark Invest was bringing in billions of dollars in new assets under management.

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session.